Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy

High BMI is a well-known risk factor for the development and recurrence of several solid tumours, including CRC. Obesity is associated with increased levels of vascular endothelial growth factor (VEGF). Bevacizumab is the main targeted therapy for inhibiting tumour angiogenesis by blocking the VEGF/...

詳細記述

保存先:
書誌詳細
主要な著者: Faruk Aykan, N., Yildiz, Ibrahim, Sen, Fatma, Kilic, Leyla, Keskin, Serkan, Ciftci, Rumeysa, Karabulut, Senem, Sakar, Burak, Disci, Rian
フォーマット: Artigo
言語:Inglês
出版事項: Springer US 2013
主題:
Original Paper
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3755215/
https://ncbi.nlm.nih.gov/pubmed/23921648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12032-013-0679-4
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料